AgriLabs has announced the commercialization of KLEBVax SRP, the first vaccine licensed for dairy cattle to prevent mastitis caused by Klebsiella pneumoniae. KLEBVax SRP, which features Siderophore Receptor and Porin (SRP) technology, gives veterinarians and producers a new tool to prevent disease and reduce antibiotic use.
A similar vaccine using Klebsiella SRP bacterial extract was previously offered as an autogenous product by AgriLabs in partnership with Epitopix.
“Klebsiella is a widespread pathogen that has been difficult to prevent in dairy operations and has cost producers significant losses,” says Sean O’Hare, executive vice president for AgriLabs. “We are excited to offer KLEBVax SRP to veterinarians and dairy producers as a new management tool to reduce the incidence of Klebsiella mastitis. As a vaccine, KLEBVax SRP will provide an alternative to antibiotics and help shift the focus from treatment to prevention.”
In fact, in a field study, KLEBVax SRP reduced incidence of infection within 90 days of calving by 71 percent versus a placebo.
Gram-negative bacteria such as Klebsiella require iron for growth and survival. Using SRP technology, KLEBVax activates the animal’s immune system to produce antibodies that bind and block the transfer of iron through bacterial cell wall porins, starving the bacteria of needed nutrients.
“The unique process of the AgSRP technology makes it well-suited for the challenges associated with disease-causing bacteria such as Klebsiella,” says Jim Sandstrom, DVM, managing director of Epitopix, LLC. “With several years of field experience with autogenous Klebsiella SRP vaccines, we are confident the new KLEBVax SRP product will help dairy veterinarians and producers manage mastitis infections caused by Klebsiella.”